Mixed effects modeling of weight change associated with placebo and pregabalin administration.
OBJECTIVE
To characterize change from baseline weight over time for pregabalin and placebo administration.


METHODS
Asymptotic fraction of baseline weight was modeled with a nonmixture model and a mixture model as a function of baseline weight, exposure, time, covariate effects, and subject-specific random effects. Model fit was assessed using standard diagnostic plots. Predictive performance was assessed using both data similar to the original data, and open-label data.


RESULTS
The nonmixture model indicated that a typical patient (baseline weight 82 kg) receiving placebo or 300 mg/day pregabalin approached an asymptotic fractional change from baseline weight of [mean (95% prediction interval for typical individual)] 0.7% (-5.5% to 7.4%) or 2.5% (-3.8% to 9.1%), respectively, with a half-life of 17 days. Substantial between-subject variability is observed, with some drug-treated subjects remaining weight neutral or losing weight, at all levels of exposure. Structural fixed effects parameters for the two submodels (mixture model) were in close agreement with each other and with those for the nonmixture model. The mixture model described two subpopulations differing in interindividual variability. No significant interindividual-varying covariates influencing the mixture probabilities were identified other than exposure. Both models had adequate fit; both models performed well during external validation. Predictive performance (nonmixture model) was adequate to ~900 days.


CONCLUSIONS
The weight of a typical 82-kg patient receiving placebo or pregabalin (300 mg/day) approaches an asymptotic fractional change from baseline weight of 0.7%, or 2.5%, respectively, with a half-life of 17 days. Substantial between-subject variability remains unexplained.
Frame
Bill
B
Department of Clinical Pharmacology, Pfizer Global Research and Development, 2800 Plymouth Rd, Ann Arbor, MI 48105, USA. framebill@ameritech.net
Beal
Stuart L
SL
Miller
Raymond
R
Barrett
Jeannette
J
Burger
Paula
P
D001835:Body Weight / Q000187:drug effects*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008954:Models, Biological; D010919:Placebos; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000494:pharmacology
D010919:Placebos; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid
Eur J Pain. 2001;5(2):119-24
11465977
Pain. 2001 Aug;93(2):191-196
11427331
Ann Pharmacother. 1995 Oct;29(10):1048
8845546
Epilepsia. 2002 Sep;43(9):983-92
12199723
Neurology. 2003 May 27;60(10):1631-7
12771254
Epilepsy Res. 1993 Jan;14(1):11-5
8383597
Ther Drug Monit. 1997 Aug;19(4):394-6
9263379
Nephron. 1976;16(1):31-41
1244564
Clin Neuropharmacol. 1995 Dec;18(6):469-81
8681309
Obes Res. 1998 Sep;6 Suppl 2:51S-209S
9813653
Biometrics. 1995 Dec;51(4):1236-51
8589220
Neurosci Lett. 2000 Feb 18;280(2):107-10
10686389
Int J Obes Relat Metab Disord. 1996 Jan;20(1):63-75
8788324
J Clin Psychopharmacol. 2004 Apr;24(2):141-9
15206660
J Pharmacol Exp Ther. 2000 Dec;295(3):1086-93
11082444
Epilepsia. 2004 Jan;45(1):20-7
14692903
Am J Psychiatry. 2003 Mar;160(3):533-40
12611835
Int J Obes Relat Metab Disord. 1998 Jan;22(1):39-47
9481598
Pain. 2004 May;109(1-2):26-35
15082123
Neurology. 2003 Apr 22;60(8):1274-83
12707429
Biometrics. 2000 Mar;56(1):65-72
10783778
J Clin Psychiatry. 2001 Feb;62(2):92-100
11247108
J Clin Psychiatry. 2003 Mar;64(3):316-20
12716274
J Pharmacokinet Pharmacodyn. 2005 Apr;32(2):213-43
16283533
J Biol Chem. 1996 Mar 8;271(10):5768-76
8621444
Pharmacogenetics. 2001 Apr;11(3):265-8
11337942
JAMA. 1999 Oct 27;282(16):1523-9
10546691
Neuropharmacology. 2002 Feb;42(2):229-36
11804619
Epilepsy Res. 2002 Sep;51(1-2):31-71
12350382
J Clin Psychopharmacol. 2003 Jun;23(3):240-9
12826986
Pharm Res. 1993 Feb;10(2):276-81
8456077